Page last updated: 2024-11-05

lanthionine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

lanthionine: a thioether analogue of cystine; RN given refers to (DL)-isomer; structure; a component of lantibiotics (BACTERIOCINS) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lanthionine : An alanine derivative in which two alanine residues are linked on their beta-carbons by a thioether linkage. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID102950
CHEBI ID25013
SCHEMBL ID36933
MeSH IDM0041743

Synonyms (28)

Synonym
496-98-0
.beta.,.beta.'-thiodialanine
bis(2-amino-2-carboxyethyl)sulfide
dl-lanthionine
nsc-83247
lanthionine
sulfide, bis(2-amino-2-carboxyethyl)
nsc83248
nsc83247
alanine, 3,3'-thiobis-
sulfide, bis(2-amino-2-carboxyethyl), {[r-(r*,r*)]-}
alanine, 3, 3'-thiodi-
l-cysteine, s-(2-amino-2-carboxyethyl)-, (r)-
2-amino-3-(2-amino-3-hydroxy-3-oxo-propyl)sulfanyl-propanoic acid
s-((2r)-2-amino-2-carboxyethyl)-l-cysteine
AKOS003348866
3,3'-thiobis(2-aminopropionic acid)
L0010
3,3'-thiodialanine
CHEBI:25013
SCHEMBL36933
3,3'-thiobis(2-aminopropanoic acid)
mfcd00002615
lanthionine, 96%
lanthionin
2-amino-3-(2-amino-2-carboxyethyl)sulfanylpropanoic acid
Q57778592
D91227

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The potential use of OKN-007 in combination with neurotropic compounds such as the lanthionine ketamine esters is discussed for glioblastoma multiforme as well as for various other indications leading to dementia, such as aging, septic shock, and malaria infections."( Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines.
Castro Faria Neto, HC; Floyd, RA; Hensley, K; Towner, RA; Zimmerman, GA, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" Relative oral bioavailability (RBV) values, with the L-isomer of Met and Cys set at 100% (isosulfurous basis), are near 100% for D-Met for animals but only about 30% for humans."( Comparative species utilization and toxicity of sulfur amino acids.
Baker, DH, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" Even though Cys and its oxidized product (cystine) are equally efficacious at levels at or below their dietary requirements for maximal growth, Cys is far more toxic than cystine when administered orally in the pharmacologic dosing range."( Comparative species utilization and toxicity of sulfur amino acids.
Baker, DH, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
alanine derivativeAn amino acid derivative resulting from reaction of alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of alanine by a heteroatom. The definition normally excludes peptides containing alanine residues.
organic sulfideCompounds having the structure RSR (R =/= H). Such compounds were once called thioethers.
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (189)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (13.76)18.7374
1990's25 (13.23)18.2507
2000's46 (24.34)29.6817
2010's74 (39.15)24.3611
2020's18 (9.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.53%)5.53%
Reviews23 (12.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.53%)0.25%
Other165 (86.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]